secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2026-05-14T13:01:44+00:00
Accession:  0001736730-26-000033
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

CAMP4 Therapeutics reports preclinical data showing CMP-002 improves seizure threshold in SYNGAP1 model
--------------------------------------------------------------------------------

- CMP-002 produced statistically significant improvement in seizure threshold and severity in SYNGAP1 haploinsufficient mice.
- Data presented at TIDES conference on May 14, 2026; builds on prior motor/behavioral benefit evidence.
- Company plans to advance CMP-002 into a Phase 1/2 clinical trial in SYNGAP1-related disorder in H2 2026.
- Lead candidate CMP-002 is an antisense oligonucleotide targeting regulatory RNA to upregulate SYNGAP1 protein.
- Study used PTZ-induced seizure model; CMP-002 conferred resistance to tonic-clonic seizures and reduced severity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000173673026000033/0001736730-26-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000173673026000033/camp-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001736730-26-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer